ANDREW L. PECORA, M.D., FACP

Corporate Board Profile

Tech Score: 0/100

LISATA THERAPEUTICS, INC.

Filing Date	Source Excerpt
2013-08-30	Andrew L. Pecora, M.D., F.A.C.P. was appointed to our Board of Directors on December 8, 2011... Dr. Pecora also serves as Chief Medical Officer of PCT and Chief Scientific Officer of Amorcyte... The Board of Directors has concluded that Dr. Pecora should continue serving as a director based on his diversified experience in healthcare... No specific director compensation stated.
2014-08-29	Andrew L. Pecora, M.D., F.A.C.P. was appointed to our Board of Directors on December 8, 2011 pursuant to the terms of the merger agreement governing our acquisition of PCT. Dr. Pecora is co-founder and past Chairman and Chief Executive Officer of Progenitor Cell Therapy, LLC (“PCT”), which is a subsidiary of the Company. Dr. Pecora has served as NeoStem's Chief Visionary Officer since August 5, 2013 and as PCT's Chief Medical Officer since January 19, 2011 following the Company's acquisition of PCT.

Filing Date

Source Excerpt

2013-08-30

Andrew L. Pecora, M.D., F.A.C.P. was appointed to our Board of Directors on December 8, 2011... Dr. Pecora also serves as Chief Medical Officer of PCT and Chief Scientific Officer of Amorcyte... The Board of Directors has concluded that Dr. Pecora should continue serving as a director based on his diversified experience in healthcare... No specific director compensation stated.

2014-08-29

Andrew L. Pecora, M.D., F.A.C.P. was appointed to our Board of Directors on December 8, 2011 pursuant to the terms of the merger agreement governing our acquisition of PCT. Dr. Pecora is co-founder and past Chairman and Chief Executive Officer of Progenitor Cell Therapy, LLC (“PCT”), which is a subsidiary of the Company. Dr. Pecora has served as NeoStem's Chief Visionary Officer since August 5, 2013 and as PCT's Chief Medical Officer since January 19, 2011 following the Company's acquisition of PCT.

Data sourced from SEC filings. Last updated: 2025-08-30